FourThought Financial Partners LLC Sells 794 Shares of Doximity, Inc. (NASDAQ:DOCS)

FourThought Financial Partners LLC lowered its position in Doximity, Inc. (NASDAQ:DOCS) by 4.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 15,771 shares of the company’s stock after selling 794 shares during the period. FourThought Financial Partners LLC’s holdings in Doximity were worth $842,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Global Retirement Partners LLC lifted its stake in Doximity by 468.1% in the fourth quarter. Global Retirement Partners LLC now owns 534 shares of the company’s stock worth $29,000 after acquiring an additional 440 shares during the period. UMB Bank n.a. raised its holdings in Doximity by 69.1% in the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock worth $31,000 after purchasing an additional 235 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Doximity by 324.2% in the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock worth $34,000 after purchasing an additional 603 shares in the last quarter. Morse Asset Management Inc bought a new position in Doximity in the third quarter worth $46,000. Finally, IFP Advisors Inc raised its holdings in Doximity by 344.1% in the fourth quarter. IFP Advisors Inc now owns 1,328 shares of the company’s stock worth $71,000 after purchasing an additional 1,029 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on DOCS. Raymond James restated an “outperform” rating and set a $83.00 price target (up from $65.00) on shares of Doximity in a report on Friday, February 7th. Needham & Company LLC raised their target price on Doximity from $65.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. JPMorgan Chase & Co. lifted their price objective on Doximity from $30.00 to $48.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. The Goldman Sachs Group lifted their price objective on Doximity from $58.00 to $80.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Finally, Leerink Partners raised Doximity from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $60.00 to $90.00 in a research report on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.22.

Insider Buying and Selling at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares in the company, valued at $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 37.40% of the stock is currently owned by insiders.

Doximity Stock Performance

Shares of DOCS opened at $71.86 on Wednesday. The company’s 50-day simple moving average is $60.96 and its 200-day simple moving average is $49.97. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $85.21. The stock has a market capitalization of $13.42 billion, a PE ratio of 71.86, a P/E/G ratio of 4.10 and a beta of 1.39.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.